ANGLE CEO on breakthrough liquid biopsy partnership with Myriad Genetics

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland talked with Proactive's Stephen Gunnion about the company’s newly announced partnership with Myriad Genetics. Newland explained that the collaboration marks a critical milestone in ANGLE’s strategy to align its Parsortix liquid biopsy system with leading diagnostic companies. He said: “Myriad Genetics is the first one of those to actually sign up with us to do a joint development program.” Myriad Genetics, which generates nearly $1 billion annually in revenue and employs around 2,700 staff, currently bases most of its diagnostic tests on tumour tissue. According to Newland, the move to apply these tests on circulating tumour cells offers important benefits such as repeat testing, easier patient access, and the potential for earlier cancer detection. He highlighted that Myriad will cover the development costs, providing ANGLE with revenue during the process and opening up major commercialisation opportunities. If successful, the collaboration could see Myriad run hundreds of thousands of tests using ANGLE’s Parsortix technology. Newland added that this deal also sets a precedent for similar agreements with other diagnostic companies, which could significantly broaden ANGLE’s market reach and support widespread adoption of liquid biopsy testing in oncology. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future updates. #ANGLEPLC #MyriadGenetics #CancerTesting #LiquidBiopsy #OncologyDiagnostics #MedicalPartnership #HealthcareInnovation #BloodTestForCancer #CancerDetection #InvestorNews